ArticleTranslational cancer research2021
A novel nomogram to predict the overall survival of patients with colloid adenocarcinoma of the lung.
Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- Does lung adenocarcinoma subtyping offer clinical benefits?-a retrospective population-based cohort study from Sweden.Annals of translational medicine · 2026Article
- Nomogram predicting overall and cancer specific prognosis for poorly differentiated lung adenocarcinoma after resection based on SEER cohort analysis.Scientific reports · 2024Article
- [A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColloid adenocarcinoma of the lung is one of rare subtypes of pulmonary adenocarcinoma. The purpose of our study is to establish a predictive model for the overall survival of colloid adenocarcinoma.
methodsA total of 749 patients were separated from the Surveillance, Epidemiology, and End Results database between 2011 and 2015. Cox regression was performed to select the predictors of overall survival. The calibration curves, concordance index, the receiver operating characteristic curve, and the area under the curve were used to verify the nomogram. Kaplan-Meier curves were used to illustrate and compare the overall survival of patients in different surgical groups.
resultsMultivariate analyses demonstrated clinical characteristics such as age, sex, race, site, tumor stage, stage T, metastatic sites at diagnosis, surgical treatment were associated with prognosis. In the nomogram, we could predict the probability of overall survival for patients. The concordance index of the novel nomogram was 0.849, which meant that the model had a good discriminated ability. A good consistency was indicated by the calibration curves in the probability of 1-, 3-, and 5-year overall survival between the actual observation and the nomogram prediction. We plotted the receiver operating characteristic curve and the area under the curve was 0.905, 0.923, 0.885, respectively. The Kaplan-Meier curves indicated that overall survival was precisely distinguished by the different surgical status. The survival rate of patients in the surgery group was significantly higher than that of patients without surgery (P<0.0001). Segmentectomy had the highest survival rate than the lobectomy and wedge resection (P=0.0122).
conclusionsWe constructed and validated a nomogram to help predict overall survival for colloid adenocarcinoma. Clinicians could predict individualized survival and give treatment recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.